tiprankstipranks
Healthpeak Properties (MX:DOC)
:DOC
Mexico Market
EarningsQ2 2026 Earnings Report

Healthpeak Properties (DOC) Q2 2026 Earnings Report

0 Followers

MX:DOC Q2 2026 EPS Results

Actual EPS$1.35
Consensus EPS$0.47
Beat/MissBeat by +$0.88
One Year Ago EPS$0.84

MX:DOC Q2 2026 Revenue Results

Actual Revenue$13.04B
Expected Revenue$12.26B
Beat/MissBeat by +$776.03M
YoY Revenue Growth+11.12%

Earnings Announcement Details

QuarterQ2 2026
Date08/04/2026
TimeAfter Close
Conference CallTuesday, August 4, 2026
MX:DOC Upcoming Earnings
Healthpeak Properties's next earnings date is estimated for October 22, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

MX:DOC Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Aug 04, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call highlighted meaningful operational progress: strong balance sheet metrics (net debt/EBITDA 4.7x), sizable liquidity, large JV partnerships (Brookfield/Blackstone) that raise $1B+ in proceeds while preserving control, strong outpatient leasing (1.2M SF in Q2; occupancy to 90.7%), lab leasing momentum and occupancy improvement (78.5%, +140 bps YTD), and significant senior housing/Janus performance (45% revenue growth, 34% adjusted EBITDA growth). Challenges remain, notably lab occupancy still below peak, selective elevated CapEx needs for redevelopments, elevated borrowing costs limiting leverage options, cautious tenant timelines, and only a modest FFO guidance raise. Overall the positive operational momentum, strategic partnerships, and strong liquidity and balance sheet outweigh the remaining execution and market risks.
Company Guidance
On guidance, Healthpeak raised full‑year FFO as adjusted by $0.02 to $1.73–$1.77 per share, driven by a 75‑basis‑point increase in total same‑store NOI at the midpoint (including +200 bps each for lab and senior housing) and recognition of lower market interest amortization tied to a $400 million seller‑note repayment; the company reported Q2 FFO as adjusted of $0.46, ended the quarter with net debt/adjusted EBITDA of 4.7x (leverage below 5x vs. a 5.5x long‑term target), expects roughly $1.9 billion of gross capital‑recycling proceeds through year‑end, has completed $1.0 billion of acquisitions and buybacks to date, repaid $900 million of debt (including $650 million of senior notes in July), holds $4.1 billion of available liquidity, and cited ongoing optionality to deploy capital into preleased outpatient development, JV acquisitions, or opportunistic buybacks (having repurchased $100 million in April at a >10% FFO yield when the stock was under $17).
Strong Balance Sheet and Liquidity
Net debt to adjusted EBITDA of 4.7x (below 5x), $4.1 billion of available liquidity, $900 million of debt repaid through Aug 4 (including $650 million of senior unsecured notes in July), and guidance that the company can maintain leverage below its 5.5x long-term target.
Strategic JV Partnerships and Capital Recycling
Completed a $1 billion Brookfield outpatient medical recapitalization while retaining 51% ownership of the 5.6M SF portfolio at a trailing cash cap rate of 5.9%; announced partnerships with Blackstone and Brookfield that expand alternative equity capital access; expect $1.9 billion gross proceeds from capital recycling by year-end.
Outpatient Medical Leasing Momentum
Executed 1.2 million square feet of leases in Q2 (2.3M YTD), 80% tenant retention, cash re-leasing spreads of 5% (in line with 10-quarter average and above pre-merger 2–3%), and outpatient total occupancy up 20 bps sequentially to 90.7%; additional 204k SF executed since July 1 and ~882k SF under LOI.
Life Science (Lab) Leasing Progress
Executed 381k SF of lab leases in Q2 (≈60% new leasing, ≈30% on vacant space); lab total occupancy rose 80 bps sequentially to 78.5% (140 bps increase since year-end 2025); ~480k SF under LOI and leasing pipeline continuing to convert.
Janus Living / Senior Housing Outperformance
Healthpeak now owns 74% of Janus Living (~$6.5 billion equity value). Janus delivered 45% total revenue growth and 34% adjusted EBITDA growth in the quarter, with cash on the balance sheet and no outstanding debt; same-store senior housing occupancy +260 bps and NOI +19%.
Shareholder Returns and Opportunistic Buybacks
Repurchased $100 million in April at a >10% FFO yield when the stock was < $17 per share; company retains flexibility for future buybacks when stock trades below intrinsic value.
Upgraded FFO Guidance and NOI Drivers
Raised full-year FFO as adjusted guidance by $0.02 to a range of $1.73–$1.77 per share, driven by a 75-basis-point increase in total same-store NOI at the midpoint, including a 200-basis-point improvement in both lab and senior housing at the midpoint.

MX:DOC Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Oct 22, 2026
2026 (Q3)
0.91 / -
-2.872
2026 (Q2)
0.47 / 1.35
0.84560.00% (+0.51)
2026 (Q1)
0.90 / 4.73
1.014366.67% (+3.72)
2025 (Q4)
1.18 / 2.70
0.1691500.00% (+2.53)
2025 (Q3)
1.00 / -2.87
2.027-241.67% (-4.90)
2025 (Q2)
1.08 / 0.84
3.548-76.19% (-2.70)
2025 (Q1)
0.91 / 1.01
0.169500.00% (+0.84)
2024 (Q4)
0.81 / 0.17
2.196-92.31% (-2.03)
2024 (Q3)
1.20 / 2.03
2.0270.00% (0.00)
2024 (Q2)
1.69 / 3.55
1.52133.33% (+2.03)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed